Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0466 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.9467 |
| Open | 5.7267 |
| 1-Year Change | 173.25% |
| Day's Range | 5.2767 - 5.9167 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 5.3067 | -0.5200 | -8.92% | 5.8267 | 5.9767 | 5.2567 |
| Feb 20, 2025 | 5.9467 | -0.1500 | -2.46% | 6.0967 | 6.0967 | 5.5767 |
| Feb 19, 2025 | 6.1467 | 1.4400 | 30.59% | 4.7067 | 7.0767 | 4.7067 |
| Feb 18, 2025 | 4.9267 | -0.3500 | -6.63% | 5.2767 | 5.2767 | 4.5567 |
| Feb 14, 2025 | 5.1167 | 0.4700 | 10.11% | 4.6467 | 5.2067 | 4.5567 |
| Feb 13, 2025 | 4.6367 | -0.5600 | -10.78% | 5.1967 | 5.1967 | 4.6267 |
| Feb 12, 2025 | 5.1067 | 0.5100 | 11.09% | 4.5967 | 5.2667 | 4.4967 |
| Feb 11, 2025 | 4.5967 | 0.0400 | 0.88% | 4.5567 | 5.1767 | 4.4967 |
| Feb 10, 2025 | 4.4967 | 0.2600 | 6.14% | 4.2367 | 4.6267 | 4.1167 |
| Feb 7, 2025 | 4.4567 | -0.6700 | -13.07% | 5.1267 | 5.2167 | 4.4067 |
| Feb 6, 2025 | 5.3367 | 0.1200 | 2.30% | 5.2167 | 6.0667 | 5.0967 |
| Feb 5, 2025 | 5.0267 | 1.2000 | 31.36% | 3.8267 | 6.3667 | 3.8267 |
| Feb 4, 2025 | 3.7667 | 1.4200 | 60.51% | 2.3467 | 3.7767 | 2.2067 |
| Feb 3, 2025 | 2.1267 | 0.0200 | 0.95% | 2.1067 | 2.2467 | 2.0767 |
| Jan 31, 2025 | 2.2267 | 0.0800 | 3.73% | 2.1467 | 2.3467 | 2.1467 |
| Jan 30, 2025 | 2.2467 | 0.1000 | 4.66% | 2.1467 | 2.3467 | 2.1467 |
| Jan 29, 2025 | 2.2367 | -0.0700 | -3.03% | 2.3067 | 2.3267 | 2.1967 |
| Jan 28, 2025 | 2.3567 | 0.0500 | 2.17% | 2.3067 | 2.4267 | 2.2967 |
| Jan 27, 2025 | 2.3567 | 0.0500 | 2.17% | 2.3067 | 2.5067 | 2.2867 |
| Jan 24, 2025 | 2.5467 | 0.0700 | 2.83% | 2.4767 | 2.5467 | 2.4167 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
| Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com